Endogenous toxic metabolites and implications in cancer therapy

Area of Science:

• Biochemistry
• Oncology
• Metabolic Engineering

Background:

• Metabolic enzymes are crucial for cancer cell proliferation, supplying essential building blocks like nucleotides.
• The role of metabolic enzymes in detoxifying harmful substrates is often overlooked.
• Many endogenous metabolites possess inherent toxicity due to reactive groups or competitive inhibition.

Purpose of the Study:

• To highlight the underappreciated role of metabolic enzymes in preventing the accumulation of toxic metabolites.
• To propose a novel cancer-killing strategy based on inducing the accumulation of toxic metabolic intermediates.
• To explore the potential for cancer cell-selective toxicity by targeting overactive metabolic pathways.

Main Methods:

• Reviewing evidence and mechanisms of metabolite toxicity.
• Analyzing metabolic pathways with toxic intermediates, such as selenocysteine metabolism.
• Illustrating the concept of targeting downstream enzymes to induce toxic metabolite accumulation.

Main Results:

• Identified several toxic metabolites, including methylglyoxal, 4-hydroxynonenal, glutaconyl-CoA, deoxyuridine triphosphate, and l-2-hydroxyglutarate.
• Demonstrated that targeting downstream enzymes can lead to the accumulation of these toxic metabolites.
• Showcased the potential for cancer-selective toxicity when metabolic pathways are dysregulated in cancer.

Conclusions:

• Metabolic pathways containing toxic intermediates can be therapeutically exploited to selectively kill cancer cells.
• Targeting enzymes that normally detoxify metabolites presents a promising avenue for novel cancer treatments.
• Further research into exploiting toxic metabolites holds significant potential for developing new anti-cancer therapies.